Phaseline

Companies › Apriligen

Apriligen: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Hematology; next expected readout Apr 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
APR-2020
Autologous CD34+ hematopoietic stem cells transduced ex vivo with RPS19 gene to correct ge
–Phase 1RPS19 Deficient Diamond-Blackfan AnemiaApr 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07476183APR-2020Phase 1RPS19 Deficient Diamond-Blackfan AnemiaHematologyApr 2027

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.